Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Digital Realty Trust | Eli Lilly and Company | Vistra | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The 10-K states that "the majority of our facilities operate as “merchant” facilities without long-term power sales agreements" and that Vistra is "not guaranteed any rate of return on our capital investments". Against that, the scarcity is real: six NRC-licensed nuclear units totalling 6,448 MW, licences running 2036-2053, inside a 43,641 MW fleet, plus 20-year PPAs with AWS (1,200 MW) and Meta (2,609 MW). The 2025 gas additions - Lotus (2,600 MW, closed October 2025) and pending Cogentrix (5,500 MW) - extend the merchant gas side, not the nuclear scarcity. Only the 433 MW of uprates extends the moat asset. |
| Moat type | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The intangibles are non-replicable regulatory assets rather than patents: six nuclear licences (Comanche Peak 2050/2053, Perry 2046, Davis-Besse 2037, Beaver Valley 2036/2047), fuel "contracted to support all our refueling needs through 2030", section 45U credits "recognizing the value of existing carbon-free nuclear power", and TXU Energy, sold "for over 20 years" and "registered and protected by trademark law". Read 45U as a floor, not moat strength: the 2025 credit was $220m against $545m in 2024, and it "provides increasing levels of support as unit revenues decline". Efficient scale does not apply. |
| Leadership | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Vistra describes itself as "one of the largest producers of power in deregulated markets in the U.S." with over 230 TWh generated, "one of the largest competitive power generators in the U.S. as measured by MWh of generation capacity", "one of the largest electricity generators in the U.S.", and "one of the largest competitive residential retail electricity providers". That hedged phrasing appears four times and is the strongest claim the filing makes. The 10-K names no competitor and assigns no rank, so co-leader is the ceiling the disclosure supports. |
| Pricing power | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak Vistra is a merchant price taker. Price formation rests on "the highest variable cost unit that clears the market", prices are "unpredictable and may fluctuate substantially", hedging markets have "limited liquidity after two to three years", and competing retailers "may offer different products, lower electricity prices and other incentives". ERCOT's $2,000/MWh figure is the low system-wide offer cap, applied conditionally when the peaker net margin exceeds three times CONE or under the PUCT Emergency Pricing Program, not a standing cap. PJM has "announced that it would propose" extending its capacity cap to 2028-29 and 2029-30, subject to FERC approval. |
| Summary | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Vistra's moat is one scarce asset wrapped in a commodity business. Six NRC-licensed nuclear units - 6,448 MW, licences running 2036-2053 - sit inside a 43,641 MW fleet that the 10-K says operates in the majority as "merchant" facilities with no long-term power sales agreements and no guaranteed rate of return. That block cannot be rebuilt by a rival, and is now partly de-risked by 20-year PPAs with AWS (1,200 MW from Comanche Peak) and Meta (2,609 MW from the PJM plants) plus section 45U credits. Everything else - 26,989 MW of gas, 8,743 MW of coal, the 5m-customer retail book - competes on price in markets Vistra does not set, against entrants the filing says keep building "despite relatively low power prices". The 2025 growth was gas M&A (Lotus, pending Cogentrix), which widens the commodity-exposed side. Narrow, for a specific reason: the moat is 15% of the fleet. |
| Chain position | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Merchant IPP: sells energy, capacity and ancillary services into ISO/RTO spot and short-term wholesale markets (ERCOT, PJM, ISO-NE, NYISO, CAISO, MISO) and resells to ~5m retail customers. Emerging role as long-term nuclear offtake supplier to hyperscalers (AWS, Meta). Not a price setter at any link. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |